Maxim Group Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $3

BenzingaJan 11 02:25 · Ratings

Lineage Is Maintained at Neutral by Mizuho

Dow JonesJan 9 00:28 · Ratings

Mizuho Securities Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $67

Futu NewsJan 8 21:34 · Ratings

Express News | Lineage Inc : UBS Cuts Target Price to $64 From $75

BreakingsJan 6 22:13

Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital

Yahoo FinanceJan 4 21:10

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

BenzingaJan 3 22:07 · Ratings